📊 GELS Key Takeaways
Is Gelteq Ltd (GELS) a Good Investment?
Gelteq Ltd presents an unanalyzable investment case due to complete absence of financial data across all fundamental metrics. With zero revenue reporting, no balance sheet data, and only 1 metric available out of comprehensive coverage, the company appears to be in pre-revenue or distressed financial state. The lack of any meaningful financial disclosure prevents fundamental analysis and indicates substantial risk.
Gelteq's SEC-reported fundamentals are very weak: fiscal 2025 revenue was only AUD 165,645 against a net loss of AUD 6.6 million, with operating cash outflow worsening to AUD 5.5 million. The balance sheet shows positive equity, but liquidity is strained by a AUD 4.1 million working capital deficit and the auditor explicitly flagged substantial doubt about the company's ability to continue as a going concern, making growth quality and financial health poor.
Why Buy Gelteq Ltd Stock? GELS Key Strengths
- No strengths identified
- Positive reported equity of AUD 15.8 million at June 30, 2025
- Cash balance improved to AUD 344,648 from AUD 24,522 year over year
- Revenue resumed in fiscal 2025 after zero revenue in fiscal 2024, indicating some commercial activity
GELS Stock Risks: Gelteq Ltd Investment Risks
- Complete absence of revenue and profitability data
- No balance sheet information available - unable to assess financial health or solvency
- Zero operating cash flow data - cannot evaluate cash generation capability
- Minimal financial disclosure with only 1 metric available
- No insider buying activity in last 90 days
- Inability to perform any standard fundamental analysis
- Potential pre-revenue or shell company status
- Auditor and company disclosed substantial doubt about going concern status
- Severe liquidity pressure with current assets of AUD 1.5 million versus current liabilities of AUD 5.6 million
- Recurring losses, minimal revenue scale, and heavy reliance on external financing to fund operations
Key Metrics to Watch
- Revenue recognition and growth trajectory
- Balance sheet strength and working capital
- Operating cash flow and cash burn rate
- Revenue growth and customer order conversion into cash collections
- Operating cash burn and working capital deficit
Gelteq Ltd (GELS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
GELS Profit Margin, ROE & Profitability Analysis
GELS vs Healthcare Sector: How Gelteq Ltd Compares
How Gelteq Ltd compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Gelteq Ltd Stock Overvalued? GELS Valuation Analysis 2026
Based on fundamental analysis, Gelteq Ltd has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Gelteq Ltd Balance Sheet: GELS Debt, Cash & Liquidity
GELS Revenue Growth, EPS Growth & YoY Performance
GELS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Gelteq Ltd (CIK: 0001920092)
❓ Frequently Asked Questions about GELS
What is the AI rating for GELS?
Gelteq Ltd (GELS) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GELS's key strengths?
Claude: . ChatGPT: Positive reported equity of AUD 15.8 million at June 30, 2025. Cash balance improved to AUD 344,648 from AUD 24,522 year over year.
What are the risks of investing in GELS?
Claude: Complete absence of revenue and profitability data. No balance sheet information available - unable to assess financial health or solvency. ChatGPT: Auditor and company disclosed substantial doubt about going concern status. Severe liquidity pressure with current assets of AUD 1.5 million versus current liabilities of AUD 5.6 million.
What is GELS's revenue and growth?
Gelteq Ltd reported revenue of N/A.
Does GELS pay dividends?
Gelteq Ltd does not currently pay dividends.
Where can I find GELS SEC filings?
Official SEC filings for Gelteq Ltd (CIK: 0001920092) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GELS's EPS?
Gelteq Ltd has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GELS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Gelteq Ltd has a SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GELS stock overvalued or undervalued?
Valuation metrics for GELS: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GELS stock in 2026?
Our dual AI analysis gives Gelteq Ltd a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GELS's free cash flow?
Gelteq Ltd's operating cash flow is N/A, with capital expenditures of N/A.
How does GELS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).